1346674-62-1

Basic information

• Product Name: 2,6-dibromo-4-fluorobenzyl acetate
• Synonyms: 2,6-dibromo-4-fluorobenzyl acetate
• CAS NO: 1346674-62-1
• Molecular Weight: 325.96
• Mol File: 1346674-62-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,6-dibromo-4-fluorobenzyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dibromo-4-fluorobenzyl acetate(1346674-62-1)
• EPA Substance Registry System: 2,6-dibromo-4-fluorobenzyl acetate(1346674-62-1)

Safety Data

• Hazardous Substances Data: 1346674-62-1(Hazardous Substances Data)

Usage

Molecular weight

344.93 g/mol

Structure

A benzyl group (a carbon ring with two bromine atoms and one fluorine atom attached) with an acetate group (a carbonyl group esterified with an acetic acid) attached to it.

Appearance

A crystalline solid

Physical properties

Poorly soluble in water, soluble in organic solvents such as ethanol, dichloromethane, and acetone.

Chemical properties

Reacts with nucleophiles, can undergo substitution reactions, and can be used as a building block in organic synthesis.

Uses

Building block in organic synthesis, pharmaceutical manufacturing, development of new drugs, agrochemicals, and materials.

Importance

Unique structure and reactivity make it a target for research and development in the chemical and pharmaceutical industries.

Upstream product

• 1346674-69-8 (2,6-dibromo-4-fluorophenyl)methanol 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 938467-02-8 2,6-dibromo-4-fluorobenzaldehyde 
• 62720-29-0 1,3-dibromo-5-fluoro-2-iodobenzene 

Downstream Products

• 1346673-13-9 2-bromo-4-fluoro-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346673-08-2 [4-fluoro-2-(4-methyl-6-{[4-(morpholin-4-yl)phenyl]amino}-5-oxopyrazin-2-yl)-6-{6-oxo-8-thia-5-azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-5-yl}phenyl]methyl acetate 
• 1346669-71-3 5-[5-fluoro-2-(hydroxymethyl)-3-(4-methyl-6-{[4-(morpholin-4-yl)phenyl]amino}-5-oxo-4,5-dihydropyrazin-2-yl)phenyl]-8-thia-5-azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-6-one 
• 1346673-39-9 (2-{5-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-methyl-6-oxopyridin-3-yl}-4-fluoro-6-{6-oxo-8-thia-5-azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-5-yl}phenyl)methyl acetate 
• 1346673-40-2 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-fluoro-6-(1-oxo-3,4,5,6,7,8-hexahydrobenzothieno[2,3-c]pyridin-2(1H)-yl)benzyl acetate 
• 1346669-85-9 5-(3-{5-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-5-fluoro-2-(hydroxymethyl)phenyl)-8-thia-5-azatricyclo-[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-6-one 
• 1346674-40-5 4-fluoro-2-(5-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346670-27-6 2-(5-fluoro-2-(hydroxymethyl)-3-(5-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346671-95-1 4-fluoro-2-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346670-46-9 2-(5-fluoro-2-(hydroxymethyl)-3-(1-methyl-5-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346674-75-6 {4-fluoro-2-[1-methyl-5-({5-[(1-methylazetidin-3-yl)oxy]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-6-{6-oxo-8-thia-5azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-5-yl}phenyl}methyl acetate 
• 1346670-48-1 5-[5-fluoro-2-(hydroxymethyl)-3-[1-methyl-5-({5-[(1-methylazetidin-3-yl)oxy]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]phenyl]-8-thia-5-azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-6-one 
• 1346673-38-8 4-Fluoro-2-(1-oxo-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-2(1H)-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1346675-77-1 {2-[5-({5-[2-(dimethylamino)ethoxy]pyridin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-fluoro-6-{6-oxo-8-thia-5-azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-5-yl}phenyl}methyl acetate 

Relevant articles and documents

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties

In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike properties of our previous chemical matter. Compounds exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.

BICYCLIC PIPERAZINE COMPOUNDS

Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.